Fraisier C, Abraham D A, van Oijen M, Cunliffe V, Irvine A, Craig R, Dzierzak E A
National Institute for Medical Research, Division of Eukaryotic Molecular Genetics, London, UK.
Gene Ther. 1998 Jul;5(7):946-54. doi: 10.1038/sj.gt.3300676.
Strategies to inhibit the spread of HIV infection consist of a number of specific molecular approaches. Since viral production is dependent upon Tat-mediated transactivation of the HIV promoter through the Tat activating region (TAR), tat antisense RNA, anti-tat ribozymes, TAR decoys and dominant negative Tat mutant proteins have been suggested as therapeutic inhibitors. We produced and tested several Tat mutant proteins, including a newly generated form Tat delta 58, for the ability to inhibit Tat-mediated transactivation and HIV production. In addition, we generated a new Tat fusion mutant between a C-terminus truncated form of Tat (Tat delta 53) and the Drosophila Engrailed (Eng) transcription repressor domain to test the hypothesis that transcriptional repression can be targeted to the HIV promoter. This fusion mutant was also examined for its capacity to block both Tat-mediated transactivation and HIV replication. We show that three mutants Tat delta 53. Tat delta 58 and Tat delta 53/Eng result in a transdominant phenotype inhibiting wild-type Tat-mediated transactivation, and that the inhibiting potential is increased by the presence of the entire basic domain or the fusion of a repressor domain. However, only the transdominant mutants Tat delta 58 and Tat delta 53/Eng significantly inhibit HIV-1 replication after infection of transfected T cell lines. These results demonstrate the potent inhibiting activity of Tat mutants on HIV replication, and suggest a synergistic effect of Tat transdominant mutant fusion with the Drosophila Engrailed transcription repressor domain.
抑制HIV感染传播的策略包括许多特定的分子方法。由于病毒的产生依赖于Tat通过Tat激活区域(TAR)介导的HIV启动子反式激活,因此已提出tat反义RNA、抗tat核酶、TAR诱饵和显性负性Tat突变蛋白作为治疗性抑制剂。我们制备并测试了几种Tat突变蛋白,包括新产生的Tatδ58形式,以研究其抑制Tat介导的反式激活和HIV产生的能力。此外,我们构建了一种新的Tat融合突变体,它由Tat的C末端截短形式(Tatδ53)与果蝇Engrailed(Eng)转录抑制域组成,以验证转录抑制可靶向HIV启动子的假说。还检测了这种融合突变体阻断Tat介导的反式激活和HIV复制的能力。我们发现,三种突变体Tatδ53、Tatδ58和Tatδ53/Eng产生了显性负性表型,抑制了野生型Tat介导的反式激活,并且整个碱性结构域的存在或抑制域的融合增强了抑制潜力。然而,只有显性负性突变体Tatδ58和Tatδ53/Eng在转染的T细胞系感染后能显著抑制HIV-1复制。这些结果证明了Tat突变体对HIV复制具有强大的抑制活性,并提示Tat显性负性突变体与果蝇Engrailed转录抑制域融合具有协同效应。